Disease · MONDO_0005130

celiac disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. celiac disease. Diseases, record MONDO_0005130. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005130

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: celiac disease; Open Targets
Open Targets ID: MONDO_0005130; Open Targets
Other names: CD - Celiac disease, CD - Coeliac disease, CELIAC DIS, CS - Celiac sprue, CS - Coeliac sprue, Celiac disease (disorder), Celiac disease NOS, Celiac disease NOS (disorder), Celiac rickets, Celiac rickets (disorder), Celiac syndrome, Coeliac disease, Coeliac disease NOS, Coeliac disease [Ambiguous], Coeliac rickets, Coeliac syndrome, Disease, Celiac, Enteropathies, Gluten, Enteropathies, Gluten-Sensitive, Enteropathy, Gluten, Enteropathy, Gluten-Sensitive, GSE - Gluten-sensitive enteropathy, Gluten Enteropathies, Gluten Sensitive Enteropathy, Gluten enteropathy, Gluten-Sensitive Enteropathies, Gluten-induced enteropathy syndrome, Gluten-responsive sprue, Idiopathic steatorrhea, Idiopathic steatorrhoea, Non-tropical sprue, Nontropical Sprue, Sprue, Sprue, Celiac, Sprue, Nontropical, Steatorrhoea - idiopathic, Wheat-sensitive enteropathy, celiac sprue, coeliac sprue, gluten intolerance, gluten-induced enteropathy; Open Targets
Disease Ontology: DOID:10608; Disease Ontology
MeSH: D002446; MeSH
NCI Thesaurus: C26714; NCI Thesaurus
Orphanet: ORPHA:555; Orphanet
Highest stage of its drugs: Approval, for 1 of its 16 drugs, from DailyMed; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PHYTONADIONE	CHEMBL1550	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LATIGLUTENASE	CHEMBL3137344	Enzyme	Phase 2	ClinicalTrials.gov and TTD	8	7	7	Drugs and targets
LARAZOTIDE ACETATE	CHEMBL2103815	Protein	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ORDESEKIMAB	CHEMBL2109467	Antibody	Phase 2	ClinicalTrials.gov and TTD	5	3	3	Drugs and targets
ZAMAGLUTENASE	CHEMBL5095161	Enzyme	Phase 2	ClinicalTrials.gov and TTD	4	2	2	Drugs and targets
ZED-1227	CHEMBL4081588	Small molecule	Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
AMLITELIMAB	CHEMBL4594569	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
VERCIRNON	CHEMBL2178578	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
BIFIDOBACTERIUM SPP.	CHEMBL4297912		Phase 1/2	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CCR9	C-C chemokine receptor type 9	1	C-C chemokine receptor type 9 antagonist	Phase 2	https://conductscience.org/library/genes/10803	Drugs and targets
CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 partial agonist	Phase 2	https://conductscience.org/library/genes/1136	Drugs and targets
CHRNB4	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 partial agonist	Phase 2	https://conductscience.org/library/genes/1143	Drugs and targets
CTSS	Cathepsin S	1	Cathepsin S inhibitor	Phase 1	https://conductscience.org/library/genes/1520	Drugs and targets
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	1	Dihydroorotate dehydrogenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/1723	Drugs and targets
IL12B	Interleukin-23	1	Interleukin-23 inhibitor	Phase 1	https://conductscience.org/library/genes/3593	Drugs and targets
IL15	Interleukin-15	1	Interleukin-15 inhibitor	Phase 2	https://conductscience.org/library/genes/3600	Drugs and targets
IL23A	Interleukin-23	1	Interleukin-23 inhibitor	Phase 1	https://conductscience.org/library/genes/51561	Drugs and targets
IL2RB	Interleukin-2 receptor subunit beta	1	Interleukin-2 receptor beta chain inhibitor	Phase 1	https://conductscience.org/library/genes/3560	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04424927	PRV-015 in Gluten-free Diet Non-responsive Celiac Disease	Phase 2	388	2025-10-20	Celiac Disease	ORDESEKIMAB	Its record names the disease	ClinicalTrials.gov
NCT05353985	A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet	Phase 2	153	2025-08-20	Celiac Disease	ZAMAGLUTENASE	Its record names the disease	ClinicalTrials.gov
NCT03701555	A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease	Phase 1	139	2023-04-04	Digestive System Disease	ZAMAGLUTENASE	Its record names the disease	ClinicalTrials.gov
NCT02637141	A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease	Phase 2	64	2019-12-03	Celiac Disease	ORDESEKIMAB	Its record names the disease	ClinicalTrials.gov
NCT01137955	Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease	Not applicable	50	2022-06-29	Celiac Disease	RIFAXIMIN	Its record names the disease	ClinicalTrials.gov
NCT01917630	Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients	Phase 2	500		Celiac Disease	LATIGLUTENASE	Its record names the disease	ClinicalTrials.gov
NCT07298343	Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease	Phase 2	356		Celiac Disease	ZED-1227	Its record names the disease	ClinicalTrials.gov
NCT01396213	A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease	Phase 2	342		Celiac Disease	LARAZOTIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT06557772	A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease	Phase 2	229		Coeliac Disease, Celiac Disease	AMLITELIMAB	Its record names the disease	ClinicalTrials.gov
NCT00620451	Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease	Phase 2	105		Celiac Disease	LARAZOTIDE ACETATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
TAK-062 Placebo + SIGE Gluten-Bar vs TAK-062 + SIGE Gluten-Bar: deaths from any cause	0 of 76	0 of 76	152	NCT05353985	Trial comparisons
TAK-062 Placebo + SIGE Gluten-Bar vs TAK-062 + SIGE Gluten-Bar: serious adverse events	4 of 76	1 of 76	152	NCT05353985	Trial comparisons
Rifaximin vs Placebo: serious adverse events	0 of 20	0 of 21	41	NCT01137955	Trial comparisons
Part 4: PvP003 600 mg, TID (4B) vs Part 4: PvP003 Placebo, TID (4A): Part 4: Number of Participants Reporting One or More TEAEs for PvP003 After Multiple Doses	0 of 6	0 of 6	12	NCT03701555	Trial comparisons
Part 4: PvP003 600 mg, TID (4B) vs Part 4: PvP003 Placebo, TID (4A): Part 4: Number of Participants Reporting One or More TESAEs for PvP003 600 mg After Multiple Doses	0 of 6	0 of 6	12	NCT03701555	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25683116	RESULT	1	PubMed
22825365	RESULT	1	PubMed
21647654	RESULT	1	PubMed
17697209	RESULT	1	PubMed
41039829	DERIVED	2	PubMed
39739628	DERIVED	1	PubMed
35931103	DERIVED	1	PubMed
33741317	DERIVED	1	PubMed
31494096	DERIVED	1	PubMed
28755266	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005130

GET https://conductscience.org/api/diseases/v1/MONDO_0005130/trials?page=2

API reference For AI assistants